%0 Journal Article
%A Coll, Elisabeth
%A Fernandez-Ruiz, Mario
%A Sanchez-Alvarez, J Emilio
%A Martinez-Fernandez, Jose R
%A Crespo, Marta
%A Gayoso, Jorge
%A Bada-Bosch, Teresa
%A Oppenheimer, Federico
%A Moreso, Francesc
%A Lopez-Oliva, Maria O
%A Melilli, Edoardo
%A Rodriguez-Ferrero, Marisa L
%A Bravo, Carlos
%A Burgos, Elena
%A Facundo, Carme
%A Lorenzo, Inmaculada
%A Yañez, Iñigo
%A Galeano, Cristina
%A Roca, Ana
%A Cabello, Mercedes
%A Gomez-Bueno, Manuel
%A Garcia-Cosio, MªDolores
%A Graus, Javier
%A Llado, Laura
%A de Pablo, Alicia
%A Loinaz, Carmelo
%A Aguado, Beatriz
%A Hernandez, Domingo
%A Dominguez-Gil, Beatriz
%A Spanish Group for the Study of COVID-19 in Transplant Recipients
%T COVID-19 in transplant recipients: The Spanish experience.
%D 2020
%U http://hdl.handle.net/10668/16472
%X We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR]: 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR: 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-β (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR]: 2.5; 95% CI: 1.4-4.6), age >60 years (OR: 3.7; 95% CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95% CI: 1.9-4.9).
%K antibiotic: antiviral
%K clinical decision-making
%K clinical research/practice
%K complication: infectious
%K infection and infectious agents - viral
%K infectious disease
%~